{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:13:11Z","timestamp":1791915191938,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacl.2026.02.017","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:00:11Z","timestamp":1772096411000},"page":"1040-1047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ApoA-1 versus HDL-C as markers of cardiovascular risk"],"prefix":"10.1016","volume":"20","author":[{"given":"Selin","family":"Bilgic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Pencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6923-8517","authenticated-orcid":false,"given":"Line","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-3956","authenticated-orcid":false,"given":"Allan","family":"Sniderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.02.017_bib1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9149(03)00262-5","article-title":"Concordance\/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk","volume":"91","author":"Sniderman","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.02.017_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","article-title":"The apoB\/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy\u2014a review of the evidence","volume":"259","author":"Walldius","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2026.02.017_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.02.017_bib4","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.02.017_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MOL.0000000000000476","article-title":"Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice","volume":"29","author":"Trompet","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2026.02.017_bib6","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1210\/jc.2011-1846","article-title":"LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals","volume":"97","author":"Haase","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2026.02.017_bib7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.02.017_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.02.017_bib9","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.02.017_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jama.298.7.776","article-title":"Clinical utility of different lipid measures for prediction of coronary heart disease in men and women","volume":"298","author":"Ingelsson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.02.017_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.02.017_bib12","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bjornson","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.02.017_bib13","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","article-title":"Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol","volume":"84","author":"Bjornson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.02.017_bib14","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/ATVBAHA.124.321165","article-title":"Discordance analysis of VLDL-C and ApoB in UK Biobank and Framingham Study: a prospective observational study","volume":"44","author":"Bilgic","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.02.017_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.02.017_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","article-title":"Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges","volume":"128","author":"Rosenson","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.017_bib17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacl.2026.02.017_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-90-481-8622-8_7","article-title":"High density lipoprotein structure-function and role in reverse cholesterol transport","volume":"51","author":"Lund-Katz","year":"2010","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.jacl.2026.02.017_bib19","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2026.02.017_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","article-title":"HDL and cardiovascular disease","volume":"384","author":"Rader","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.02.017_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.02.017_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","article-title":"Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease","volume":"47","author":"Barter","year":"2006","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:04:23Z","timestamp":1778925863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1933287426000516"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.017","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ApoA-1 versus HDL-C as markers of cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}